Fate Therapeutics (FATE) PT Lowered to $23 at Piper Jaffray; 'Raises $144 Million to Advance Cancer Cell Therapies'
Tweet Send to a Friend
Piper Jaffray analyst Edward Tenthoff lowered the price target on Fate Therapeutics (NASDAQ: FATE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
